[
  {
    "ts": "2026-01-20T06:09:59+00:00",
    "headline": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
    "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
    "url": "https://finance.yahoo.com/news/bull-case-illumina-ilmn-could-060959095.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ea58a0a7-d615-3a9a-8028-2e5f7e204c7a",
      "content": {
        "id": "ea58a0a7-d615-3a9a-8028-2e5f7e204c7a",
        "contentType": "STORY",
        "title": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
        "description": "",
        "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
        "pubDate": "2026-01-20T06:09:59Z",
        "displayTime": "2026-01-20T06:09:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dF3MhqhVQlxOrPlZ6576PQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iKEosOYcHiWIA3wbQNTRmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b7362375b2727bfdfe4eb144bcc3fe6a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-illumina-ilmn-could-060959095.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-illumina-ilmn-could-060959095.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ILMN"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-20T09:57:35+00:00",
    "headline": "Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion",
    "summary": "We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Merck & Co., Inc. tops our list for being one of the best cancer stocks. TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described […]",
    "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-poised-095735084.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c86c184b-fc26-31f8-81a4-d026fbad253a",
      "content": {
        "id": "c86c184b-fc26-31f8-81a4-d026fbad253a",
        "contentType": "STORY",
        "title": "Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion",
        "description": "",
        "summary": "We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Merck & Co., Inc. tops our list for being one of the best cancer stocks. TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described […]",
        "pubDate": "2026-01-20T09:57:35Z",
        "displayTime": "2026-01-20T09:57:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1da4007264be4ef25473da75f4099ab8",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6kSgXdPQI4lGvuTGF4aVcw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1da4007264be4ef25473da75f4099ab8.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MMUB6vlICxxD2scPrXJn0Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1da4007264be4ef25473da75f4099ab8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-poised-095735084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-poised-095735084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-20T11:00:00+00:00",
    "headline": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
    "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
    "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "449ac09a-53b1-3b8e-bd31-18eb9785f02a",
      "content": {
        "id": "449ac09a-53b1-3b8e-bd31-18eb9785f02a",
        "contentType": "STORY",
        "title": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
        "description": "",
        "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
        "pubDate": "2026-01-20T11:00:00Z",
        "displayTime": "2026-01-20T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y14NrymWnVHtLPxT5mPm5g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dSewxxG3XkMHQTa3gmVr6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-20T10:03:23+00:00",
    "headline": "Merck CEO on US Business, Life Sciences Innovation",
    "summary": "Merck KGaA Chief Executive Officer Belen Garijo says the company will continue to collaborate with the US and deliver life sciences innovation to patients. She spoke to Bloomberg's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.",
    "url": "https://finance.yahoo.com/video/merck-ceo-us-business-life-100323926.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "1c2be8fd-bafd-3b91-89d4-b2b4d96fa854",
      "content": {
        "id": "1c2be8fd-bafd-3b91-89d4-b2b4d96fa854",
        "contentType": "VIDEO",
        "title": "Merck CEO on US Business, Life Sciences Innovation",
        "description": "Merck KGaA Chief Executive Officer Belen Garijo says the company will continue to collaborate with the US and deliver life sciences innovation to patients. She spoke to Bloomberg's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.",
        "summary": "Merck KGaA Chief Executive Officer Belen Garijo says the company will continue to collaborate with the US and deliver life sciences innovation to patients. She spoke to Bloomberg's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.",
        "pubDate": "2026-01-20T10:03:23Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_markets_video_2/e7b1f9a4931206242c4245df4a7ab907",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eFoQoW41.YzQxGa6.AHC3A--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_video_2/e7b1f9a4931206242c4245df4a7ab907.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/klNUNVy5DDAEiqatMtneTg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_video_2/e7b1f9a4931206242c4245df4a7ab907.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/merck-ceo-us-business-life-100323926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/merck-ceo-us-business-life-100323926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MKGAF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-20T12:10:00+00:00",
    "headline": "This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.",
    "summary": "Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.",
    "url": "https://www.barrons.com/articles/rapt-therapeutics-stock-gsk-acquisition-9ab8074f?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "77bcbf9f-6555-3f7f-a29a-6207126f03b3",
      "content": {
        "id": "77bcbf9f-6555-3f7f-a29a-6207126f03b3",
        "contentType": "STORY",
        "title": "This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.",
        "description": "",
        "summary": "Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.",
        "pubDate": "2026-01-20T12:10:00Z",
        "displayTime": "2026-01-20T12:10:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/77bcbf9f-6555-3f7f-a29a-6207126f03b3/this-biotech-stock-surges.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/6819f3061c8944e2d9eb501bd9e796a0",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lNPcq2UMIQkGNS3kCqhf3g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/6819f3061c8944e2d9eb501bd9e796a0.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wLYaJb6bQZzM.owYgA.VFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/6819f3061c8944e2d9eb501bd9e796a0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/rapt-therapeutics-stock-gsk-acquisition-9ab8074f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RAPT"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]